RenaSci Logo REV@1000px-1

RenaSci was founded in 2001 by Dr Sharon Cheetham, Dr Rob Jones and Professor David Heal, providing an integrated blend of in vivo pharmacology consultancy and experimental services, helping clients from all sectors of the pharmaceutical and biotech industry to maximise their research productivity and streamline drug development.

Renasci’s regulatory expertise, combined with its skills in drug development and abuse liability assessment, have been pivotal to the success of clients in achieving European and US drug registrations.

Based at BioCity in Nottingham, RenaSci was aquired by Sygnature Discovery in 2018 and is now a fully integrated part of Sygnature's integrated drug discovery offering.

Join us at our new home on to find all of the services you are familiar with from RenaSci, as well as our full suite of integrated drug discovery and non-clinical solutions.

Who are Sygnature Discovery?

Sygnature Discovery are a world-leading provider of integrated drug discovery and non-clinical solutions.

Our mission is simple: to add genuine value to our customers’​ research projects through intellectual input, an ethos of true partnership, and a wealth of world-class drug discovery expertise. We offer target validation, hit identification, hit-to-lead, lead optimisation and fully integrated drug discovery programmes.

It’s important to us that our team can collaborate on an equal footing with our customers’ scientists to drive their drug discovery projects towards the clinic. With that principle we have built a team of over 400 staff including pharmaceutical industry-experienced research scientists (over 80% PhD qualified).

Sygnature's capabilities include:

Since 2011, 37 compounds discovered by Sygnature for customers have entered pre-clinical development and so far 17 of these have progressed to clinical trials (Phases I, II and III).


The RenaSci team can now be reached at Sygnature Discovery. 

If you have an enquiry and would like to talk to a scientist please contact us.


Sygnature Discovery operates two integrated drug discovery sites at BioCity, Nottingham, and Alderley Park, Cheshire, in the UK, as well as an office presence in the biotech hub of Boston, MA, in the USA.



Sygnature Discovery Limited, BioCity,
Pennyfoot Street, Nottingham NG1 1GR,
United Kingdom